Drugs News and Research

RSS

Interleukin Genetics announces clinical study data on osteoarthritis progression

Interleukin Genetics, Inc. and the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill announced today findings from a large clinical study to evaluate the role of genetic factors in osteoarthritis progression which showed patients with radiographic evidence of knee osteoarthritis who inherited a specific pattern of genetic variations in the interleukin-1 receptor antagonist (IL-1Ra) gene were almost twice as likely to progress to severe disease as other patients.

23 Sep 2010

Vaxonco initiates Phase I clinical trial of novel DNA-based polyepitope vaccine against malaria

Vaxonco Inc., a Korean company specializing in peptide-based vaccines and Ichor Medical Systems (Ichor), whose advanced TriGrid™ Delivery System (TriGrid™) is being tested worldwide for its ability to enhance delivery of DNA drugs and vaccines, announced today the initiation of a Phase I clinical trial to evaluate a novel DNA-based polyepitope vaccine against malaria.

23 Sep 2010

New study signals hope for treatment of rare neurodegenerative disease

A new study led by St. Jude Children's Research Hospital scientists signals hope for treatment of a neurodegenerative disease and a new model for understanding the mechanism at work in other more common neurodegenerative disorders.

23 Sep 2010

FDA approves fingolimod drug for multiple sclerosis

The first oral medication for multiple sclerosis was approved today by the Food & Drug Administration. Physicians praised the decision to approve the drug, called fingolimod, saying it would give multiple sclerosis patients new options for treatment.

23 Sep 2010

Opinions: Genetically-modified crops can improve vaccines; MDG focus on women and girls; U.S. leadership for MDGs; Boosting access to drugs; Merits of bilateral development assistance

"The U.N. estimates that diarrheal diseases kill 1.8 million people every year. … So you might take it as good news that American company Ventria Bioscience says it has hit on an improvement to existing rehydration therapies, which could mean another tool in the fight against diarrhea," according to a Wall Street Journal editorial examining the delays the company has experienced since it first sought to have its product approved by the FDA back in 2004, even "[a]fter a panel of food, medicine, immunology, child nutrition and health experts had declared its product safe."

23 Sep 2010

Nerve inflammation may cause postsurgical neuropathies: Study

A new Mayo Clinic study found that nerve inflammation may cause the pain, numbness and weakness following surgical procedures that is known as postsurgical neuropathy. The development of postsurgical neuropathies is typically attributed to compression or stretching of nerves during surgery. This new research shows that, in some cases, the neuropathy is actually caused by the immune system attacking the nerves and is potentially treatable with immunosuppressive drugs.

23 Sep 2010

DCGI approves ADXS11-001 human testing for cervix cancer

As part of approving the human testing of ADXS11-001 the lead agent for the treatment of cervix cancer of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company the Drugs Controller General of India (DCGI) required that the agent be tested to assure its safety prior to use.

23 Sep 2010

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

Biogen Idec is committed to improving the lives of people with multiple sclerosis (MS), and no company is doing more for these patients. There has been a desire within the MS community for an oral treatment for a long time, and the approval of Gilenya has made this a reality.

23 Sep 2010

Scientists develop humanized mouse model to study typhoid fever

Better treatments and prevention for typhoid fever may emerge from a laboratory model that has just been developed for the disease. The model is based on transplanting human immune stem cells from umbilical cord blood into mice that are susceptible to infections.

23 Sep 2010

Women face sexual function problems after breast cancer

A new study published in the Journal of Sexual Medicine looked at whether women were more likely to experience sexual problems after breast cancer. The results showed that 70% of women were facing sexual function problems approximately two years post diagnosis.

23 Sep 2010

U.S. joins whistleblower suit against Pfizer for drug marketing

The Wall Street Journal: "The Justice Department is trying to take the lead in a lawsuit accusing Pfizer Inc.'s Wyeth unit of improperly promoting an organ-transplant drug for unauthorized uses and paying illegal kickbacks to doctors. The lawsuit was filed by two former Wyeth sales representatives who were responsible for promoting Rapamune, an immunosuppressant used to prevent the body's rejection of transplanted kidneys.

23 Sep 2010

AstraZeneca to use THEW database for cardiac safety evaluation

AstraZeneca purchased a one-year membership to gain access to an international repository of data designed to aid industry and academic researchers developing new technologies to improve cardiac safety.

23 Sep 2010

FDA approves Gilenya capsules for reducing MS relapses

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

22 Sep 2010

NIDA awards GeneGo SBIR grant to develop integrated systems biology platform for nicotine addiction research

GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant from the National Institute on Drug Abuse to develop an integrated systems biology platform for research into the causes and treatment of tobacco dependence, nicotine addiction, smoking cessation and tobacco/nicotine withdrawal.

22 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.

22 Sep 2010

Study finds no benefit from self-management counseling in patients with heart failure

Patients with mild to moderate heart failure who received educational materials and self-management counseling in an attempt to improve adherence to medical advice did not have a reduced rate of death or hospitalization compared to patients who received educational materials alone, according to a study in the September 22/29 issue of JAMA.

22 Sep 2010

Lilly's multidrug-resistant tuberculosis initiative honored with World Business and Development Award

An eminent international panel of judges has selected Eli Lilly and Company to receive a World Business and Development Award for demonstrating what can be achieved through successful partnerships in the battle against multidrug-resistant tuberculosis (MDR-TB).

22 Sep 2010

PA State Police, PCCD join national effort to collect medications on Sept. 25

Pennsylvanians are urged to turn in expired, unused and unwanted prescription medications at collection sites statewide during the first National Prescription Drug Take-Back Day on Saturday, Sept. 25, State Police and the Pennsylvania Commission on Crime and Delinquency said today.

22 Sep 2010

Islamic Relief USA provides $20 million medical aid to Pakistan

Islamic Relief USA (IR USA), a non-profit relief and development organization based in metro-D.C., announced today that it has delivered a $20 million aid shipment of medicine to Pakistan.

22 Sep 2010

Drugs News and Research

Interleukin Genetics announces clinical study data on osteoarthritis progression

Vaxonco initiates Phase I clinical trial of novel DNA-based polyepitope vaccine against malaria

New study signals hope for treatment of rare neurodegenerative disease

FDA approves fingolimod drug for multiple sclerosis

Opinions: Genetically-modified crops can improve vaccines; MDG focus on women and girls; U.S. leadership for MDGs; Boosting access to drugs; Merits of bilateral development assistance

Nerve inflammation may cause postsurgical neuropathies: Study

DCGI approves ADXS11-001 human testing for cervix cancer

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

Scientists develop humanized mouse model to study typhoid fever

Women face sexual function problems after breast cancer

U.S. joins whistleblower suit against Pfizer for drug marketing

AstraZeneca to use THEW database for cardiac safety evaluation

FDA approves Gilenya capsules for reducing MS relapses

NIDA awards GeneGo SBIR grant to develop integrated systems biology platform for nicotine addiction research

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Study finds no benefit from self-management counseling in patients with heart failure

Lilly's multidrug-resistant tuberculosis initiative honored with World Business and Development Award

PA State Police, PCCD join national effort to collect medications on Sept. 25

Islamic Relief USA provides $20 million medical aid to Pakistan

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News